Wall Street Bulls Look Optimistic About Cardinal (CAH): Should You Buy?

Cardinal Health (CAH) currently holds an average brokerage recommendation (ABR) of 1.43, approximating a 'Buy' rating based on 14 brokerage firms, with 78.6% recommending a 'Strong Buy'; however, the article suggests that brokerage recommendations can be biased and may not be the sole determinant for investment decisions. The Zacks Rank, driven by earnings estimate revisions, is presented as a potentially more reliable indicator, with Cardinal's current year earnings estimate increasing 0.9% over the past month to $8.16, contributing to a Zacks Rank #2 (Buy).

Analysis

Cardinal Health (CAH) exhibits a strong consensus among Wall Street analysts, with an Average Brokerage Recommendation (ABR) of 1.43 on a 1-to-5 scale, positioning it between a Strong Buy and a Buy. This ABR is derived from 14 brokerage firms, of which an overwhelming 78.6% (11 firms) rate the stock as a Strong Buy. However, the article cautions that such sell-side recommendations can be influenced by inherent positive biases due to brokerage firms' vested interests, noting that research indicates limited success of these recommendations in isolation for predicting optimal stock price increases. As a counterpoint, the article highlights the Zacks Rank, a proprietary quantitative model based on earnings estimate revisions, which assigns Cardinal Health a #2 (Buy) rating. This is supported by a tangible positive trend in earnings expectations: the Zacks Consensus Estimate for CAH's current year earnings has risen by 0.9% over the past month to $8.16 per share. The article posits that this upward revision in earnings estimates, reflecting growing analyst optimism about the company's prospects, provides a more reliable indicator for potential near-term stock appreciation than ABR alone.

Key Decisions for Investors

• Investors may consider the positive ABR for Cardinal Health (CAH) of 1.43 as an indicator of favorable Wall Street sentiment, but should primarily view it as a data point to be validated by other fundamental analysis due to potential inherent biases in sell-side ratings.
• The Zacks Rank #2 (Buy) for CAH, driven by a 0.9% increase in current year EPS estimates to $8.16 over the past month, suggests a more robust positive signal; investors should monitor ongoing trends in earnings estimate revisions as a key indicator of near-term performance.
• Given the article's emphasis on the predictive power of earnings estimate revisions, investors should prioritize these over standalone brokerage recommendations when evaluating CAH's investment potential.